EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG announces changes in its Executive Management Board

ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement.

25.09.2012

Berlin, Germany, September 25, 2012 - The Supervisory Board of Epigenomics AG (ISIN: DE000A1K0516) and its current CEO Geert Walter Nygaard today agreed that Mr. Nygaard will leave the Executive Management Board of the company effective 30 September 2012.

The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board member of the company and this capacity also takes over the responsibility of acting CEO of Epigenomics, effective 1 October 2012. Dr. Uwe Staub, currently SVP R&D was promoted to COO and was granted "Prokura" (power of attorney). His duties will be expanded by the responsibility for medical affairs and customer support.

The Supervisory Board thanks Mr. Nygaard for his commitment and contributions to Epigenomics over the last years.

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

end of announcement euro adhoc

issuer: Epigenomics AG Kleine Präsidentenstraße 1 D-10178 Berlin phone: +49 30 24345-0 FAX: +49 30 24345-555 mail: ir@epigenomics.com WWW: http://www.epigenomics.com sector: Biotechnology ISIN: DE000A1K0516 indexes: Prime All Share, Technology All Share

stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, regulated dealing/prime standard: Frankfurt
language: English

Digital press kit: http://www.ots.at/pressemappe/EASY_38683/aom

Rückfragen & Kontakt:

Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | EAE0001